Healthcare
Lifecore Biomedical, Inc.(LFCR)
Live Price
Offline$5.54
+0.36% today
1Y Change
-33.57%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $200.00M
- Revenue Growth
- +0.5%
- EPS Growth
- -425.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lifecore Biomedical, Inc. (LFCR) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $5.54 and down 33.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +0.5%, EPS growth of -425.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.5%, EPS -425.6%, free cash flow +24.9% with operating margin -3.0% and ROIC -2.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LFCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.5% vs +7.6% peer median
Operating Margin
Below sector median
-3.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 2, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +0.5% and EPS is at -425.6%, with operating margin around -3.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 2, 2026 | โ | +6.0% | +23.7% | +37.0% |
2026 Mar 16, 2026 | +40.7% | -0.2% | -7.3% | +19.0% |
2026 Jan 1, 2026 | โ | +0.8% | -2.3% | +10.1% |
Benchmark Edge
LFCR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LFCR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LFCR Max Drawdown
-58.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LFCR and SPY.
Company Overview
Lifecore Biomedical, Inc.
NASDAQ Global Select
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
- Leadership
- Paul Josephs
- IPO Date
- Feb 15, 1996
- Employees
- 524
- Street Address
- 3515 Lyman Boulevard
- Mailing
- Chaska, MN, 55318
- Region
- Chaska, MN, US
- Reporting Currency
- USD
- Investor Line
- 952 368 4300
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.3
- Price/Book
- 5.8
Growth
- Revenue
- +0.5%
- EPS
- -425.6%
- Free Cash Flow
- +24.9%
Profitability
- Gross Margin
- 32.3%
- Operating Margin
- -3.0%
- Net Margin
- -23.0%
- ROE
- -182.1%
- ROIC
- -2.1%
Balance Sheet
- Debt/Equity
- 4.23
- Current Ratio
- 3.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.